Foundation Medicine company information, Employees & Contact Information

Foundation Medicine Spotlights Scientific Achievements Across its Portfolio of High-Quality Biomarker Tests at the 2025 European Society for Medical Oncology (ESMO) Congress Business Wire

Foundation Medicine Launches Molecular Residual Disease (MRD) Test for Research Use in Early to Late-Stage Cancers Through its FlexOMx™ Lab Yahoo Finance

Foundation Medicine to Present Over 15 Abstracts at the 2025 ASCO® Annual Meeting FinancialContent

2024 Urology Times pipeline report Urology Times

ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti–Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma | JCO Precision Oncology ASCO Publications

A genomics revolution is rapidly improving cancer care statnews.com

Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers Frontiers

Foundation Medicine Appoints Dan Malarek as Chief Executive Officer citybiz

Foundation Medicine Comes to Torrey Pines San Diego Business Journal

Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring PR Newswire

FDA approves FoundationOneLiquid CDx for niraparib/abiraterone in mCRPC Urology Times

Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples ASCO Publications

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator Yahoo Finance

FDA approves companion diagnostic for olaparib/abiraterone in BRCA+ mCRPC Urology Times

Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care Business Wire

Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer Business Wire

FDA approves companion diagnostic for niraparib/abiraterone in BRCA+ mCRPC Urology Times

Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne CDx as a Companion Diagnostic for Relay’s Investigational FGFR2 Inhibitor, RLY-4008 Business Wire

Collaborate to Improve Access to Genetic Counseling for Advanced Cancer Patients Business Wire

FDA Green Lights Companion Diagnostic for Niraparib Plus Abiraterone Acetate in BRCA+ mCRPC OncLive

OneOncology and Foundation Medicine Unveil First-of-its-Kind Partnership to Advance Personalized Medicine at Community Oncology Practices Business Wire

At ASCO, Testing and AI Rival Drugs for Attention, but Reimbursement Remains a Barrier AJMC

Genomic Landscape of Lymphatic Malformations: A Case Series and Response to the PI3Kα Inhibitor Alpelisib in an N-of-One Clinical Trial medRxiv

Foundation Medicine Appoints Mia Levy as Chief Medical Officer citybiz

A compilation of 13 patients with metastatic colorectal cancer and concomitant BRAF and RAS family mutations Frontiers

Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors Frontiers

Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis Nature

Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction Nature

FDA Approves Companion Diagnostic for Tovorafenib in BRAF-Altered Pediatric Low-Grade Glioma OncLive

FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Olaparib CancerNetwork

FDA Approves FoundationOne CDx Companion Diagnostic for Selpercatinib in RET+ Solid Tumors OncLive

Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial Frontiers

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors Nature

Genomic landscape of 891 RET fusions detected across diverse solid tumor types Nature

Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies Nature

Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response Journal of Hematology & Oncology

Ancestry-associated co-alteration landscape of KRAS and EGFR -altered non-squamous NSCLC Nature

Pfizer puts Foundation Medicine at the center of its cancer companion diagnostic strategy Fierce Biotech

Liquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results - Mata - 2024 - Histopathology Wiley Online Library

Access, autonomy, and affordability: ethical and human rights issues surrounding multigene panel testing for cancer in Japan and Switzerland Frontiers

FDA Approves FoundationOne CDx as Companion Diagnostic for Alpelisib CancerNetwork

Pricey Precision Medicine Often Financially Toxic For Cancer Patients KFF Health News

Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in a Patient With Metastatic Intrahepatic Cholangiocarcinoma With High Tumor Mutational Burden Cureus

FDA Approves First CGP Test as Companion Diagnostic for BRAF Inhibitor Therapies for Melanoma AJMC

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer The New England Journal of Medicine

New Products: Test launched to improve prostate biopsy decision process Urology Times

Clinical Applications of Liquid Biopsies in Cancer Cancer Therapy Advisor

Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC) BMC Gastroenterology

A cutting-edge cancer testing company is suing one of its biggest rivals businessinsider.com